Published Mar 18, 2026

Our compound has a short half-life, but QD dosing is critical for differentiation. Is that even realistic?

In drug development, this often comes down to aligning pharmacokinetic (PK) constraints with the desired dosing paradigm. A short half-life can suggest the need for multiple daily doses, but it does not automatically rule out once-daily dosing. Achieving a QD regimen typically requires a deliberate, data-driven formulation strategy to sustain exposure and manage variability.

Why is QD the "Holy Grail"?

It's simple: Compliance. Patients are significantly more likely to adhere to a QD regimen than a BID (twice-daily) or TID (three-times-daily) schedule. In competitive therapeutic areas, QD dosing isn't just a "nice-to-have"; it's the barrier to entry.

The Solution: Bridging the Gap with Modified Release (MR)

To turn a "short-acting" molecule into a "once-a-day" treatment, we must move beyond Immediate Release (IR). The goal is to flatten the PK curve—lowering the Cmax (to reduce side effects) and maintaining levels above the Minimum Effective Concentration (MEC) for up to 24 hours.

Is your molecule a candidate for QD? Check these 4 pillars:

1. 1. The Absorption Window: This is  often the biggest deal-breaker. Does the drug only absorb in the upper GI tract, or can it be absorbed throughout the intestine, including in the colon? If the window is narrowed to the upper GI, we may need Gastro-retentive systems to keep the dosage form in the stomach longer.

2. 2. Solubility & Stability: As the formulation travels through the changing pH of the GI tract, the drug must remain stable and in solution to be absorbed.

3. 3. Potency & Dose: MR tablets are generally larger than the IR tablets. If you need a very high dose to maintain efficacy for 24 hours, the pill might become too big for a human to swallow (the "horse pill" problem).

4. 4. Physiologic Constraints: We have to account for GI transit time (usually 6-12 hours). If the drug hasn't  been fully released and absorbed by the time it reaches the end of the line, QD won't work.

Proven Strategies to Consider:

• Matrix Systems: Using hydrophilic polymers to create a "gel layer" that controls drug diffusion. Release is generally controlled by diffusion and erosion.

• Reservoir Systems: Utilizing film coating and osmotic pressure to deliver the drug at a constant rate, independent of pH.

• Multiparticulate Systems: Filling capsules with functional-coated pellets or mini-tablet of single or  multiple release profiles to achieve desired release.

The Bottom Line:

A short half-life is a hurdle, not a wall. By integrating PK modeling with advanced materials science early in the CMC phase, we can transform challenging molecules into patient-friendly, QD therapies.